Advertisement

Collaboration › Details
Acadia–JPMorgan Chase: investor conference, 202501 supply service Acadia Pharmaceuticals presents at JP Morgan Healthcare Conference 2025
![]() |
Period | 2025-01-14 |
![]() |
Region | San Francisco, CA |
Country | United States (USA) | |
![]() |
Partner, 1st | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) |
Group | Acadia (Group) | |
Partner, 2nd | J.P. Morgan Securities LLC | |
Group | JPMorgan Chase (Group) | |
![]() |
Product | J.P. Morgan 43rd Annual Healthcare Conference 2025 San Francisco |
Product 2 | CNS drug (neurological drug) | |
![]() |
Person | Owen Adams, Catherine (Acadia 202412 CEO) |
Person 2 | Kildani, Al (Halozyme 201902 VP Investor Relations + Corporate Communications) | |
Acadia Pharmaceuticals Inc.. (12/19/24). "Press Release: Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025". San Diego, CA.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time.
A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and X.
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
[email protected]
Record changed: 2024-12-24 |
Advertisement

More documents for Acadia (Group)
- [1] Acadia Pharmaceuticals Inc.. (12/19/24). "Press Release: Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025". San Diego, CA....
- [2] Acadia Pharmaceuticals Inc.. (12/9/24). "Press Release: Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer". San Diego, CA....
- [3] Acadia Pharmaceuticals Inc.. (11/26/24). "Press Release: Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711". San Diego, CA....
- [4] Saniona AB. (11/26/24). "Press Release: Saniona Announces Licensing Agreement with Acadia Pharmaceuticals for SAN711 in Neurological Diseases"....
- [5] Acadia Pharmaceuticals Inc.. (9/9/19). "Press Release: Acadia Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis". San Diego,...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top